MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Search

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

206.89 -0.41

Overview

Share price change

24h

Current

Min

205.27

Max

211.83

Key metrics

By Trading Economics

Income

56M

-39M

Sales

57M

158M

Profit margin

-24.585

Employees

1,017

EBITDA

51M

2.3M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+22% upside

Dividends

By Dow Jones

Next Earnings

13 lis 2025

Market Stats

By TradingEconomics

Market Cap

1.5B

13B

Previous open

207.3

Previous close

206.89

News Sentiment

By Acuity

50%

50%

166 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 paź 2025, 23:25 UTC

Major Market Movers

Salesforce Rises on New FY30 Financial Targets

15 paź 2025, 18:52 UTC

Earnings
Major Market Movers

Prologis Shares Gain on Raised Outlook, Data Center Growth

15 paź 2025, 18:30 UTC

Acquisitions, Mergers, Takeovers

Constellation Software to Buy U.K.'s Tecvia Holding

15 paź 2025, 17:19 UTC

Acquisitions, Mergers, Takeovers

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15 paź 2025, 17:11 UTC

Acquisitions, Mergers, Takeovers

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15 paź 2025, 23:48 UTC

Market Talk

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15 paź 2025, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 paź 2025, 22:37 UTC

Market Talk

Economic Stars Are Aligning for RBA -- Market Talk

15 paź 2025, 21:44 UTC

Earnings

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15 paź 2025, 20:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

15 paź 2025, 20:44 UTC

Acquisitions, Mergers, Takeovers

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15 paź 2025, 20:44 UTC

Acquisitions, Mergers, Takeovers

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15 paź 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15 paź 2025, 20:34 UTC

Earnings

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15 paź 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15 paź 2025, 20:17 UTC

Acquisitions, Mergers, Takeovers

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15 paź 2025, 19:06 UTC

Earnings

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15 paź 2025, 19:04 UTC

Market Talk

Oil Futures Post Back-to-Back Losses -- Market Talk

15 paź 2025, 18:46 UTC

Market Talk

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15 paź 2025, 18:23 UTC

Earnings

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15 paź 2025, 17:37 UTC

Acquisitions, Mergers, Takeovers

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15 paź 2025, 17:34 UTC

Market Talk

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15 paź 2025, 16:57 UTC

Earnings

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15 paź 2025, 16:51 UTC

Acquisitions, Mergers, Takeovers

EssilorLuxottica Doesn't Disclose Financial Details

15 paź 2025, 16:50 UTC

Acquisitions, Mergers, Takeovers

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15 paź 2025, 16:49 UTC

Acquisitions, Mergers, Takeovers

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15 paź 2025, 16:48 UTC

Acquisitions, Mergers, Takeovers

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15 paź 2025, 16:48 UTC

Acquisitions, Mergers, Takeovers

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15 paź 2025, 16:47 UTC

Acquisitions, Mergers, Takeovers

EssilorLuxottica Buys Ikerian

15 paź 2025, 16:34 UTC

Market Talk

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

22% upside

12 Months Forecast

Average 254.63 USD  22%

High 307 USD

Low 220 USD

Based on 16 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

166 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat